Navigation Links
GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Date:2/11/2009

ATLANTA, Feb. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, presented a corporate update at the Eleventh Annual BIO CEO & Investor Conference 2009, held at the Waldorf-Astoria Hotel, in New York.

Dr. McNally presented a corporate overview of GeoVax and its DNA/MVA vaccine technology, showcasing the scientific rationale and encouraging data from the Company's completed studies and trials. Among the points discussed by Dr. McNally were:

  • World class science and collaboration with leading institutions. Dr. McNally informed the audience of unique scientific collaboration between Emory University, the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), which led to the formation of GeoVax and the exclusive license of technology developed at these institutions.
  • Large market opportunity. Dr. McNally presented information on the very attractive market opportunity available for a successful HIV/AIDS vaccine. GeoVax's unique vaccine with its potential use in both preventative and therapeutic applications holds promise for not only addressing an unmet medical need, but also for commercial success.
  • Intellectual property. Dr. McNally briefly reviewed GeoVax's patent portfolio, consisting of over 20 issued and pending patents covering the Company's vaccine technology and manufacturing methods.
  • Status of Phase 2a preventative clinical trial. Dr. McNally discussed the current status of the Company's Phase 2a preventative human vaccine trial. He noted that clinical sites had been activated and prospecti
    '/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Sidney Kimmel Cancer Center at Thomas Jefferson University ... , Through the Strategic Alliance Partnership program, the ... will collaborate to raise awareness of the Center’s ... and other projects. Clinicians and other health care ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... January 12 Bavarian Nordic,owns several United States ... core technology, MVA-BN(R), which is the basis for ... a vector for delivering,recombinant vaccines. Bavarian Nordic has ... infringement action. The claim in this case is ...
... ALAMEDA, Calif., Jan. 12 Singulex, Inc. today announced ... led by JAFCO Co., Ltd. and supported by existing ... round will support the commercialization of Singulex technologies in ... Hozoji, investment officer for JAFCO Life Science Investment, will ...
... Pharmaceuticals today,announced that it has achieved its first candidate ... GlaxoSmithKline. Anacor may,receive future milestone payments and royalties ... sales. , "We are pleased ... result of,the alliance we have built between our team ...
Cached Biology Technology:Bavarian Nordic's Case Against Oxford BioMedica 2Singulex Closes $19 Million Financing Round 2Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... , April 17, 2013 Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, announced the signing of ... U.S. Army Medical Research and Materiel Command (USAMRMC). ... Reduction Using OVA1 in a Treatment Algorithm for Adnexal ...
... 100% biodiesel (B100) "blend stock" samples by the U.S. ... that 95% of the samples from 2011-12 met ASTM ... guidelines for industry and are designed to ensure quality ... operation of the nation,s vehicles powered by biodiesel blends. ...
... 16, 2013 - BGI Health and ACIBADEM Healthcare ... Company Molecular Biology, signed a Memorandum of Understanding ... technologies to Turkey and improving Turkish reproductive healthcare. ... testing technologies in the areas of Monogenic disorders, ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4NREL survey shows dramatic improvement in B100 biodiesel quality 2BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2